Orthotype v2:0 An AI-enabled algorithm predicting adverse immune responses to orthopaedic implants
Lead Participant:
PXD LIMITED
Abstract
PXD Ltd have developed the world's first and only algorithm (Orthotype) to determine pre-operatively the risk of a patient developing sensitivity to Cobalt-Chromium (CoCr) knee or joint replacements.
Triangulating specific genetic biomarkers with other data, Orthotype helps prevent future failure of implants in patients due to allergic responses governed by their individual genetic make-up.
Clinician feedback of the recently released Orthotype screening service has highlighted a need to extend the algorithm to identify possible sensitivity to other metals commonly found in hip/knee joint replacement -- zirconium and titanium -- which can also elicit immune responses in some patients.
This industrial research project will enable PXD to work with NHS clinicians to collect data from patients with and without failed implants that contain zirconium and titanium.
PXD will use gene sequencing of blood samples to confirm the association between genetic biomarkers in patients with failed zirconium and titanium implants. They will test blood samples to identify the levels of circulating metal ions related to the implant in patients with failed and non-failed implants.
This data will then be used to create new algorithms to update Orthotype v1.0 software, thus creating Orthotype v2.0\.
Orthotype v2.0 extends the game-changing and innovative personalised medicine approach offered by Orthotype v1.0: no other test enables orthopaedic surgeons to predict future implant failure risk to guide implant selection.
Orthotype v2.0 will be rapidly rolled-out, as Orthotype v1.0 is already commercialised. Available to clinicians as an SaaS product offering, all supply chain partners are in place. Orthotype v2.0 will simply replace Orthotype v1.0 on the cloud as soon regulatory clearance of the new algorithms is achieved.Orthotype v2.0 will positively impact the UK's competitiveness within the global economy: it is the only product of its kind, with a clear runway for rapid export (Orthotype v1.0 FDA submission already underway).
Triangulating specific genetic biomarkers with other data, Orthotype helps prevent future failure of implants in patients due to allergic responses governed by their individual genetic make-up.
Clinician feedback of the recently released Orthotype screening service has highlighted a need to extend the algorithm to identify possible sensitivity to other metals commonly found in hip/knee joint replacement -- zirconium and titanium -- which can also elicit immune responses in some patients.
This industrial research project will enable PXD to work with NHS clinicians to collect data from patients with and without failed implants that contain zirconium and titanium.
PXD will use gene sequencing of blood samples to confirm the association between genetic biomarkers in patients with failed zirconium and titanium implants. They will test blood samples to identify the levels of circulating metal ions related to the implant in patients with failed and non-failed implants.
This data will then be used to create new algorithms to update Orthotype v1.0 software, thus creating Orthotype v2.0\.
Orthotype v2.0 extends the game-changing and innovative personalised medicine approach offered by Orthotype v1.0: no other test enables orthopaedic surgeons to predict future implant failure risk to guide implant selection.
Orthotype v2.0 will be rapidly rolled-out, as Orthotype v1.0 is already commercialised. Available to clinicians as an SaaS product offering, all supply chain partners are in place. Orthotype v2.0 will simply replace Orthotype v1.0 on the cloud as soon regulatory clearance of the new algorithms is achieved.Orthotype v2.0 will positively impact the UK's competitiveness within the global economy: it is the only product of its kind, with a clear runway for rapid export (Orthotype v1.0 FDA submission already underway).
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| PXD LIMITED | £699,927 | £ 489,949 |
Participant |
||
| NORTH TEES HOSPITALS NHS FOUNDATION TRUST | £299,918 | £ 299,918 |
People |
ORCID iD |
| David Langton (Project Manager) |